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Molecular markers in the 
diagnosis of thyroid nodules
Marcadores moleculares no diagnóstico de nódulos tireoidianos
Laura S. Ward1, Richard T. Kloos2
SUMMARY
An indeterminate thyroid nodule cytology result occurs about every sixth fine-needle aspiration. 
These indeterminate nodules harbor a 24% risk of malignancy (ROM); too high to ignore, but 
driving surgery where most nodules are benign. Molecular diagnostics have emerged to ideally 
avoid surgery when appropriate, and to trigger the correct therapeutic surgery when indicated, 
as opposed to an incomplete diagnostic surgery. No current molecular test offers both high sen-
sitivity and high specificity. A molecular diagnostic test with high sensitivity (e.g. Afirma Gene 
Expression Classifier sensitivity 90%) offers a high Negative Predictive Value when the ROM is 
relatively low, such as < 30%. Only such tests can “rule-out” cancer. In this setting, a molecularly 
benign result suggests the same ROM as that of operated cytologically benign nodules (~6%). 
Thus, clinical observation can replace diagnostic surgery; increasing quality of life and decrea-
sing medical costs. However, its low specificity cannot “rule-in” cancer as a suspicious result 
has a Positive Predictive Value (PPV) of ~40%, perhaps too low to routinely reflex to definitive 
cancer surgery. Conversely, high specificity tests (BRAF, RAS, PPAR/PAX-8, RET/PTC, PTEN) offer 
high PPV results, and only these tests can “rule-in” cancer. Here a positive molecular result war-
rants definitive therapeutic surgery. However, their low sensitivity cannot “rule-out” cancer and 
a negative molecular result cannot dissuade diagnostic surgery; limiting their cost-effectiveness. 
Whether or not there is a useful and cost-effective role to sequentially combine these approaches, 
or to modify existing approaches, is under investigation. Arq Bras Endocrinol Metab. 2013;57(2):89-97
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SUMáRio
Resultados indeterminados na citologia de um nódulo tireoidiano ocorrem em cerca de um a cada 
seis punções aspirativas por agulha fina. Esses nódulos indeterminados apresentam risco de malig-
nidade (RM) de cerca de 24%, um valor alto demais para ser ignorado e que leva à cirurgia  em casos 
em que a maioria dos nódulos é benigna. O diagnóstico molecular é uma forma ideal de se evitar a 
cirurgia quando apropriado e de se levar ao correto procedimento cirúrgico terapêutico quando in-
dicado, em oposição à cirurgia diagnóstica incompleta. Atualmente, não existem testes moleculares 
com alta sensibilidade e especificidade. Um teste molecular de alta sensibilidade (por exemplo, a 
sensibilidade do teste Afirma Gene Expression Classifier é de 90%) tem um alto Valor Preditivo Nega-
tivo quando o RM é relativamente baixo, por exemplo, < 30%. Apenas esses testes podem “excluir” 
o câncer. Nesse contexto, um resultado molecular benigno sugere o mesmo RM de nódulos com re-
sultado benigno na citologia e operados (~6%). Assim, a observação clínica pode substituir a cirurgia 
diagnóstica, aumentando a qualidade de vida e diminuindo os custos médicos. Entretanto, a baixa 
especificidade não pode “incluir” o câncer como um resultado suspeito quando esse resultado tem 
um Valor Preditivo Positivo (VPP) ~40%, que é talvez baixo demais para levar, rotineiramente, à cirur-
gia definitiva para o câncer. Por outro lado, testes com alta especificidade (BRAF, RAS, PPAR/PAX-8, 
RET/PTC, PTEN) têm alto VPP, e apenas esses testes podem “incluir” o câncer. Nesse caso, um resul-
tado molecular positivo leva à recomendação de cirurgia terapêutica definitiva. Entretanto, sua baixa 
sensibilidade não pode “excluir” o câncer, e um resultado molecular negativo não pode dissuadir o 
médico de executar a cirurgia diagnóstica, limitando seu custo-benefício. Ainda se investiga se existe 
ou não um modo útil e com alto custo-benefício de se combinar essas abordagens sequencialmente, 
ou de se modificar as abordagens existentes. Arq Bras Endocrinol Metab. 2013;57(2):89-97
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iNTRoDUCTioN
P rior to the advent of thyroid nodule fine-needle aspiration (FNA) biopsy, these nodules were rou-
tinely referred for diagnostic surgery because of their 
5%-15% risk of malignancy (ROM) (1). FNA decreased 
diagnostic thyroidectomies by one-half as most FNAs 
are conclusively diagnosed as benign cytologically (2). 
Still, 15%-30% of thyroid FNAs are cytologically inde-
terminate, i.e. not clearly benign nor malignant (1,3). 
When cytologically indeterminate thyroid nodules 
undergo diagnostic surgery, three-quarters prove to 
be benign (4,5). Therefore, a significant opportunity 
exists to improve the care of patients with cytologically 
indeterminate nodules using novel genomic diagnostic 
technology. Current opportunities include the accurate 
pre-operative identification of (i) benign nodules to sa-
fely avoid diagnostic surgery, (ii) malignant nodules to 
direct an optimal initial treatment (e.g. total thyroidec-
tomy instead of a diagnostic hemithyroidectomy with a 
subsequent second surgery for completion thyroidec-
tomy), and (iii) rare neoplasms requiring evaluations 
and/or treatments that differ from typical differentia-
ted thyroid cancer (e.g. medullary thyroid cancer, me-
tastases to the thyroid). 
Cost, morbidity, and risk of mortality from surgery
The costs of diagnostic surgery include direct costs of 
the procedure (and its complications), indirect costs of 
time lost from work and responsibilities of daily living, 
and impaired quality of life (the fear of potentially ha-
ving cancer and the anxiety of undergoing surgery, and 
the post-operative pain and suffering from surgery, and 
the potentially impaired quality of life from iatrogenic 
hypothyroidism with (6), or without (7), a normal se-
rum TSH and its consequences). 
Thyroid surgeries carry a perioperative mortality 
rate of 0.1%-0.2%, with rates as high as 0.5% (8-10). Se-
rious or permanent non-lethal complications of thyroi-
dectomy include hypocalcemia, recurrent laryngeal 
nerve damage, re-bleeding and wound infection (11). 
These complications are more frequent than commonly 
appreciated, and are strongly related to surgeon expe-
rience (volume) and expertise. In Brazil, complications 
occurred in 34.7% of the thyroidectomies performed in 
a University Hospital, including hypoparathyroidism in 
8.8% (12). Complication rates of thyroid surgeries in a 
US population-based study were found to be 10.1% for 
surgeons who did between one and nine cases per year, 
and 5.9% for surgeons who did more than one hun-
dred cases per year (13). In fact, over 50% of thyroid 
surgeries in the US are performed by surgeons who do 
five or fewer cases per year (14), placing many patients 
at a higher risk of complications. In Spain, a study of 
surgeons performing less than 5 thyroid surgeries per 
year demonstrated hypocalcemia rates of 50% and 19% 
at 6 and 12 months, respectively (15). Figures in Brazil 
are likely similar.
Current management of cytologically benign thyroid 
FNA biopsies 
The gold-standard to determine benign versus malig-
nant status for all thyroid nodules, including those with 
benign FNAs, is surgical histology. Current ATA and 
AACE guidelines recommend close clinical and sono-
graphic follow-up of cytologically benign nodules six to 
eighteen months following the FNA biopsy, despite an 
average ROM [1- negative predictive value (NPV)] for 
operated cytologically benign nodules of 6%-8% across 
multiple studies (4,16-21) (Figure 1), and ranging as 
high as 33% (17). Thus, the average NPV, or accuracy 
of a benign diagnosis for thyroid FNA is 92%-94% 
(4,17,18). The NPV of the Afirma Gene Expression 
Classifier (GEC) applied to cytologically indetermina-
te thyroid nodules (Bethesda categories III and IV) is 
therefore similar to that of a benign cytological diag-
nosis (Figure 2) (20). It follows that these two thyroid 
nodule scenarios should be treated similarly. Watchful 
waiting in lieu of diagnostic thyroidectomy is conside-
red safe for cytologically benign thyroid nodules be-
cause thyroid cancer is relatively indolent, except for 
anaplastic thyroid cancer whose malignant nature is 
usually both clinically and cytologically obvious. Thus, 
Figure 1. Risk of malignancy among cytologically benign thyroid FNAs 
across 36 publications (17).
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even when the benign cytological diagnosis is wrong, 
if the patient undergoes surgery within twelve months 
their five-year risk of mortality and local recurrence is 
unchanged (1). In fact, papillary thyroid carcinoma 
(PTC) of any size that is confined to the thyroid gland 
(no extraglandular extension or lymph node metastases 
at presentation) has a favorable outcome whether or 
not they are treated in the first year after diagnosis (22). 
Indeed, the indolent nature of PTC has prompted ob-
servational trials in microPTC (23).
lar lesion of undetermined significance (AUS/FLUS, 
category III), follicular and Hürthle cell neoplasm or 
suspicious for same (FN/SFN, category IV), and suspi-
cious for malignancy (category V) (26). Unfortunately, 
it appears that this expansion created less reproducible 
categorization (27), and has not solved the problem. 
The Bethesda system postulated that the FN/SFN 
category would require diagnostic surgery, while the 
ROM in the AUS/FLUS category would be significan-
tly lower and best served by a repeat FNA that may 
resolve the majority of cases. Currently, this differential 
approach is being questioned. The literature strongly 
suggests that the ROM for AUS/FLUS lesions is sig-
nificantly higher than postulated by the Bethesda Clas-
sification creators (20,24,28-30). Additionally, some 
literature suggests that the ROM in AUS/FLUS may 
not be significantly lower than FN/SFN (21,29). Bon-
giovanni and cols. reported a 22% ROM (29), a finding 
consistent with a recent large multicenter prospective 
study where the ROM for AUS/FLUS was 24% whi-
le the ROM for FN/SFN was 25% (20). Thus, if the 
ROM for AUS/FLUS lesions is higher than originally 
projected, or if the ROM is similar to that of the FN/
SFN category, then is it optimal to surgically resection 
FN/SFN nodules while repeating the FNA for AUS/
FLUS nodules (28)? 
In addition, some studies (28,31) [but not all 
(30,32)] suggest that the ROM in a benign FNA after 
an initial AUS/FLUS biopsy is of intermediate risk be-
tween the two categories (i.e. the second benign FNA 
cannot make the first AUS/FLUS FNA go away). The-
se studies suggest that the remaining ROM in a follow-
-up benign FNA remains high enough that diagnostic 
surgery may not be avoidable.
AppliCATioN oF iMMUNohiSToCheMiSTRY To 
FNA CYTologY
A number of immunohistochemical approaches have 
been applied to indeterminate cytology specimens in 
an effort to reclassify these samples, including galec-
tin-3, HBME-1, and CK19 (33,34). This approach is 
best at identifying classic PTC, but sensitivity progres-
sively declines when one encounters fvPTC, FTC, and 
less common malignant variants. Further, specificity is 
impaired as some immunohistochemical approaches are 
positive in benign tissues, including follicular adeno-
mas, hyperplastic nodules, and normal thyroid tissue. 
Most importantly, blinded, prospective, large-scale, 
Figure 2. Afirma Gene Expression Classifier (GEC) reclassifies cytologically 
indeterminate thyroid nodules with a low risk of malignancy (ROM) to GEC 
Benign (20). ROM is 1-negative predictive value (NPV).
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Cytologically indeterminate FNAs are problematic, so 
can they be reclassified?
Physicians recognize that indeterminate FNA results do 
not resolve the clinical question proposed: is the no-
dule benign or malignant? One solution would be to 
label fewer FNAs as cytologically indeterminate. Cyto-
logically indeterminate samples comprise 10%-26% of 
all samples, averaging 17% (4). Some cytopathology 
experts claim that they can safely render indetermi-
nate diagnoses much less often, but considering the 
potentially high number of false negative results (mis-
sed cancers) in operated cytologically benign nodules 
(4,17,18), there may be significant risk with very low 
cytology indeterminate rates, assuming the rate is lo-
wered by moving many of these samples to the benign 
cytology category (24).
Classification systems with one indeterminate cyto-
logy category have postulated that subdividing this ca-
tegory into subcategories at higher and lower risk could 
improve clinical care (25,26). The Bethesda system cre-
ated three indeterminate categories: atypia or follicu-
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multicenter clinical trials investigating immunohisto-
chemical markers are lacking (34). Thus, most cytopa-
thologists view immunohistochemistry as having a very 
limited role in thyroid cytology (29).
MicroRNA analyses
MicroRNAs are small RNA sequences (19-25 nucleoti-
des) that function to regulate the expression of genes. 
Amid mixed results, several studies have suggested that 
aberrant miR expression profiles may separate thyroid 
cancers from benign thyroid lesions and normal thyroid 
tissue (34-36). However, this approach has yet to be 
tested on indeterminate FNAs in a large, prospective, 
blinded, multicenter study (34,35).
DNA mutation/rearrangement testing
Malignant thyroid nodules with indeterminate Bethes-
da categories III and IV cytology have a low incidence 
of BRAF mutation (37,38). This is not unexpected as 
these thyroid nodule categories include malignant tu-
mors that less commonly (or never) harbor BRAF mu-
tations such as follicular thyroid cancer, Hürthle cell 
thyroid cancer, follicular variant PTC, and medullary 
thyroid cancer. However, the low incidence is also ex-
plained by the finding that BRAF mutated PTCs have 
cytological features that cytopathologists recognize 
and classify as suspicious for malignancy or malignant 
(Bethesda categories V and VI); cytological categories 
typically treated with total thyroidectomy regardless of 
BRAF status (37). Conversely, PTCs with indetermi-
nate cytology are more often BRAF negative (37,38). 
A test that cannot detect cancer with very high sen-
sitivity cannot successfully “rule out” cancer. DNA mu-
tations such as BRAF, RAS, and RET/PTC and PAX8/
PPARG translocations have high positive predictive va-
lue (PPV) and when detected they predict (“rule in”) 
the histological diagnosis of thyroid cancer. However, 
when they are absent, cancer cannot be “ruled out” be-
cause of the low sensitivity and NPV of these markers. 
A review of four studies combining all four mutation-
-markers into a single panel had 64% sensitivity, thus 
failing to identify 36% of thyroid cancers (39). The 
largest study of mutational markers was a retrospecti-
ve analysis of prospectively collected samples where the 
mutational status was available to the clinicians, inclu-
ding the histopathologist (38). The mutational marker 
NPV for Bethesda categories IV and V were 86% and 
72%, respectively. Thus, malignancy could not be ade-
quately excluded to avoid surgery. For Bethesda cate-
gory III test sensitivity was 63%, specificity 99%, and 
NPV 94% with a 14% prevalence of malignancy. When 
applied to the 24% prevalence of malignancy seen in the 
large, multicenter (academic and community), prospec-
tive, and blinded study of Alexander and cols. (20) the 
resultant NPV declines to 89% (Figure 3). High PPV 
tests with inadequate NPV performance can “rule in” 
cancer and perhaps alter the extent of surgery, but they 
cannot “rule out” cancer, so surgery cannot be avoi-
ded. Currently, the strongest argument for their use is 
where the decision has been made for surgery, but the 
extent of surgery may be determined by the test result 
(38,40). Based on the potential ability to prevent com-
pletion thyroidectomies by performing an initial total 
thyroidectomy in patients with indeterminate cytology 
when a DNA mutation is present, Yip and cols. repor-
ted the possibility of cost savings by mutation panel tes-
ting in a decision-tree model (40). Still, no prospective 
study using patients has assessed the clinical utility of 
DNA mutation panels on thyroid surgery. The avai-
lable clinical validity data are limited to retrospective 
analyses of methodologies from academic laboratories 
(38,39), and no data are available to assess the analyti-
cal or clinical validity of commercially available DNA 
mutation panels. BRAF mutations are uncommon in 
Bethesda categories III and IV (37,38), and RET/PTC 
and PAX8/PPARG translocations are rare in all cyto-
logically indeterminate categories (29,34,38). BRAF 
Molecular diagnostic of thyroid nodules
Figure 3. Negative predictive value (NPV) of Afirma (20) and a Mutational 
Panel (38) according to the prevalence of malignancy.
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mutations are more prevalent in Bethesda category V 
(38) where the ~62% ROM (4,20) is high enough that 
most of these patients are already treated with a total 
thyroidectomy. Kleiman and cols. reported that preo-
perative screening for BRAF mutations was unlikely to 
alter patient management at their center (37).
Veracyte Afirma gene expression Classifier (geC)
The Afirma GEC, based on the measurement of mRNA 
expression, was developed and clinically validated to 
identify pre-operatively histologically benign nodules 
amongst those with indeterminate cytology. By pre-
-operatively identifying these patients, clinical and so-
nographic follow-up may be recommended in lieu of 
diagnostic surgery, thus ending the diagnostic odyssey 
(Figure 4) (41,42). The Afirma GEC analysis is indica-
ted only for nodules with indeterminate cytology, and 
is not performed on cytologically benign, malignant or 
nondiagnostic (insufficient) FNA samples. 
The Afirma GEC is provided by Veracyte’s CLIA-
-certified clinical laboratory. The molecular classifier 
proceeds in a step‐wise fashion, first applying 6 casset-
tes before applying the final benign versus malignant 
classifier. These cassettes differentiate specific rare neo-
plasm subtypes and act as filters that halt further sample 
processing if any cassette returns a “suspicious” result. 
This prevents some of the rare, nonfollicular cell‐deri-
ved neoplasms from being scored by the main classifier. 
These cassettes classify samples representing (1) ma-
lignant melanoma, (2) renal cell carcinoma, (3) breast 
carcinoma, (4) parathyroid tissue, and (5) medullary 
thyroid carcinoma. A final cassette (6) was also trained 
using Hürthle cell adenomas and carcinomas. Failing to 
trigger one of these rare neoplasm cassettes, the GEC 
evaluates the expression of 142 genes that are used in a 
proprietary algorithm to classify indeterminate thyroid 
nodule FNAs as either “Benign” or “Suspicious”.
Analytical validity
The GEC performance was evaluated in a series of 
forty-three individual reagent and analytical verification 
studies. Extensive reagent and analytical performance 
studies were conducted to evaluate the reliability and 
reproducibility of the GEC under a variety of experi-
mental and clinical conditions, with robust and highly 
reproducible results (43). Interfering substances inclu-
ding human blood and genomic DNA were not found 
to interfere with extraction or amplification steps of the 
assay. Analytical sensitivity studies demonstrated tole-
rance to variations in RNA input across the range of 5 
ng to 25 ng, as well as dilution of malignant FNA mate-
rial down to 20% with FNA material from lymphocytic 
thyroiditis and nodule hyperplasia. Analytical sensitivity 
and specificity studies with blood (up to 83%) and ge-
nomic DNA (30%) demonstrated negligible assay in-
terference, although false positive results could result 
from very bloody FNAs. FNA preservative solution 
maintained high quality and quantity of RNA material 
under various stressed time, temperature, and shipping 
conditions with no significant effect on GEC scores, or 
“Benign” versus “Suspicious” calls (100% concordan-
ce). Based on these data, room-temperature storage at 
the clinical site and chilled-box shipping was verified for 
routine practice.
Clinical validity
A whole genome approach identified candidate genes, 
and support vector machine learning methods were 
used to develop the classifier algorithm. The initial pu-
blication included test validation on an independent 
sample set of cytologically indeterminate thyroid nodu-
le FNAs with a prospective multicenter, double blind 
study design (44). The Afirma GEC achieved high sen-
sitivity and NPV. After further optimization, the 142 
gene classifier was validated in a second prospective 
multicenter validation study. The study included the 
largest ever prospectively collected set of thyroid FNA 
biopsies from 3,789 unique patients. Based on the ex-
pected 24% prevalence of malignancy in cytologically 
indeterminate samples in clinical practice, a 95% NPV 
Figure 4. Implementing the Afirma gene expression classifier (GEC) into 
clinical practice. Indeterminate is Bethesda categories III and IV (26). 
Superscript references: a (60), b (1), c (4), d (18), e (17), f (5), g (42), h (20).
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for the Afirma GEC was achieved on an independent 
sample set of 265 cytologically indeterminate nodules 
when the molecular results were compared to blinded 
gold standard histopathology diagnosis (20). Thus, the 
ROM for a thyroid nodule with Bethesda categories III 
and IV indeterminate cytology but an Afirma GEC Be-
nign classifier result is about 5%. This risk is comparable 
to the 6%-8% cancer risk for a thyroid nodule with a be-
nign cytology diagnosis (Figures 1-4) (4,16-21). This 
suggests that GEC Benign cytologically indeterminate 
(Bethesda categories III and IV) nodules can be mana-
ged as would a cytologically benign nodule, as sugges-
ted by the NCCN Thyroid Carcinoma Guideline (42). 
Specificity is the percentage of truly benign nodules 
identified by the test. The GEC raised specificity from 
0% for cytologically indeterminate categories to 52% 
when the GEC was Benign. This indicates that just over 
half of the benign nodules from Bethesda categories III 
and IV can be identified and removed from the surgical 
pool. For Bethesda category V nodules (suspicious for 
malignancy), the sensitivity and specificity performance 
of the GEC was comparable, but the high prevalence 
of malignancy in this category lowers the NPV to 85% 
(Figure 2). Thus, while the ROM is reduced from an 
initial 62% based on the cytological category to 15% 
when the GEC is benign, surgery may not be avoidable 
based on the residual ROM and therefore these nodu-
les are not routinely reflexed to GEC testing. However, 
some physicians request the GEC to be performed in 
this cytological category to screen the sample with the 
rare neoplasm cassettes, and because they may alter the 
extent of surgery from a total thyroidectomy to a diag-
nostic hemithyroidectomy when the GEC is benign.
Optimally, physicians routinely collect the Afirma 
GEC with every FNA they perform, or have on-site rapid 
cytological assessment so that the GEC can be collected 
on every patient with indeterminate cytology during one 
patient visit (Figure 4). This avoids the inconvenience, 
delayed diagnosis, and costs associated with repeating 
the FNA when the first FNA comes back indeterminate. 
Additionally, it is well known that cytologically indeter-
minate nodules may not be categorized as indetermina-
te if they undergo a repeat FNA (28). At first blush, a 
repeat FNA would seem like a good idea to potentially 
re-stratify cytologically indeterminate patients as either 
cytologically benign or malignant. Unfortunately, this 
creates a conundrum for patients whose repeat FNA is 
cytologically benign as their ROM may not be fully re-
duced to the same risk as if their first FNA had been cyto-
logically benign (28,31). The conundrum is accentuated 
by the fact that the GEC is not indicated for cytologically 
benign material as this is not cost-effective due to the low 
PPV that results from the low prevalence of malignancy 
in this setting, and because the GEC specificity of 70% 
for cytologically benign nodules will predictably result 
in a false-positive GEC Suspicious call in many cytology 
benign nodules (20). For these reasons, the GEC speci-
men must be collected at the same time as paired cyto-
logy, optimally collected during the first thyroid FNA. 
When GEC testing is desired in a patient for whom only 
cytology was previously collected, the cytology must be 
repeated along with the GEC collection.
Rare neoplasms
The cytological diagnosis of medullary thyroid cancer 
(MTC) is challenging. The tumor is uncommon and its 
cytological features overlap with those of other neoplas-
ms. When the cytopathologist wrongly suspects MTC, 
these false positive diagnoses lower cytological specifici-
ty (45-48). More significant is that non-specific cytolo-
gical features may wrongly suggest tumors other than 
MTC. These false negative diagnoses result in the failu-
re to cytologically diagnose MTC, and lower cytological 
sensitivity for MTC (45,47-54). An abstract reporting 
14 samples (from 13 patients) that positively expressed 
the MTC gene expression signature in the Afirma GEC 
rare neoplasm cassettes found that all 14 were confir-
med as MTC on histopathology (55). Experience with 
a larger number of MTC cases is needed before stronger 
conclusions can be drawn about the test’s specificity, al-
though high specificity would fill an important clinical 
gap as the main drawback of serum calcitonin screening 
for MTC is its high false positive rate (56). However, of 
the 265 histologically confirmed specimens reported by 
Alexander and cols, none of the 263 non-MTC speci-
mens triggered the MTC cassette, so early findings sug-
gest high specificity (20). In the more than 5000 GEC 
samples processed as of December 1, 2012, all samples 
that have triggered the MTC cassette have been confir-
med (or are pending confirmation) to be MTC, while 
Veracyte is unaware of a histologically confirmed MTC 
that failed to trigger the cassette (unpublished data). 
These findings suggest that the MTC rare neoplasm 
cassette has both high PPV and high NPV. A pre-opera-
tive diagnosis of MTC impacts the patient pre-operative 
evaluation, including evaluation for multiple endocrine 
neoplasia type 2 (MEN2), and the risk of concomitant 
pheochromocytoma and hyperparathyroidism. Additio-
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nally, surgical management is altered to include a mi-
nimum of total thyroidectomy and central neck dissec-
tion. Finally, pre-operative RET proto-oncogene status 
alters management of unintentionally devascularized 
parathyroid glands (57).
Experience with the other rare neoplasm cassettes is 
more limited, however, the renal cell carcinoma, breast 
carcinoma, and parathyroid tissue cassettes have all 
been triggered and surgical confirmation of these diag-
noses have been confirmed in nearly all cases (unpubli-
shed data).
Clinical utility and cost-effectiveness
The impact of the Afirma GEC on the physician deci-
sion to refer to surgery when the FNA cytology is in-
determinate but the Afirma GEC result is benign has 
been studied. Duick and cols. reported on the initial 
2,040 consecutive indeterminate thyroid FNA biopsies 
collected in clinical practice through March 2012 (58). 
Fifty-two percent of these cytologically indetermina-
te samples were GEC benign. Fifty-one physicians (46 
community-based, 5 academic) at 21 practice locations 
participated. Decisions were analyzed for 368 patients 
(395 nodules). Physicians adopted watchful waiting in 
lieu of diagnostic thyroid surgery 92.4% of the time 
when the Afirma GEC result reclassified the cytologi-
cally indeterminate nodule as benign. In contrast to the 
74% historical rate of diagnostic surgery on cytologi-
cally indeterminate thyroid nodules (4), 7.6% of those 
that were Afirma GEC benign proceeded to surgery, a 
dramatic 90% reduction in the decision to operate (p < 
0.001) (58). The decision to operate was not statistically 
different from the 9% operative rate on patients with be-
nign cytology diagnoses reported in a recent meta-re-
view (4). Physicians who choose to proceed to surgery 
with an Afirma GEC benign result reported similar rea-
sons to operate as those found for operated cytologically 
benign nodules (e.g. large nodule, compression, other 
suspicious nodule, rapid nodule growth) (58).
An independent study found no difference in missed 
cancers between the current care paradigm and the Afir-
ma GEC in a Markov model employing 10,000 Monte 
Carlo simulations of the expected range of probabilities 
for different potential outcomes (59). They also mode-
led the cost effectiveness and impact on quality adjus-
ted life years (QALYs) over a five year period for usual 
care versus utilization of the Afirma GEC in the United 
States. Compared to the traditional care paradigm, the 
Afirma GEC modestly improved quality of life while re-
ducing direct healthcare costs by $4,653 per five year 
episode of care (allowing $1,453 in direct savings assu-
ming the test cost $3,200) (59). This cost savings esti-
mate was conservative because it projected a 14% rate 
of operation on GEC benign thyroid nodules (based on 
expert opinion), a rate almost twice the 7.6% rate subse-
quently reported in actual clinical practice (58). Using 
the actual rate of thyroidectomy when the GEC is be-
nign, each test would have saved $2,600 (58). 
CoNClUSioN
The introduction of thyroid FNA dramatically reduced 
unnecessary diagnostic thyroid surgery by rendering an 
actionable ROM when the cytological diagnosis was be-
nign, suspicious for malignancy, or malignant. Among 
patients with cytologically benign lesions the ROM is 
low, and this combined with the generally indolent na-
ture of thyroid cancer has led clinicians to follow these 
patients conservatively and avoid diagnostic surgery. 
In the minority of the patients where FNA cytology 
is indeterminate, most patients have been referred for 
diagnostic surgery given the higher ROM (3). The ap-
plication of molecular diagnostics to these cytologically 
indeterminate samples offers the opportunity impro-
ve patient care by clarifying this diagnostic ambiguity. 
Immunohistochemistry, microRNA, DNA mutation/
rearrangement testing, and RNA gene expression clas-
sification have attempted to end the diagnostic odyssey 
of these patients. Immunohistochemical and mutational 
approaches have inadequate sensitivity and NPV for ma-
lignancy, such that diagnostic surgery cannot be avoided 
(3). When a mutation/rearrangement is present, howe-
ver, the high positive predictive value for malignancy 
can “rule-in” malignancy and alter patient management 
by commanding an initial total thyroidectomy as oppo-
sed to a diagnostic hemithyroidectomy (34). Currently, 
the most validated and effective approach to “rule-out” 
cancer and avoid diagnostic surgery in patients with in-
determinate cytology is the Afirma GEC based on its 
high NPV (34). Opportunities clear exist in the literatu-
re and Guidelines to clarify these concepts of “rule-in” 
versus “rule-out” tests, when they should be used, and 
which tests meet these definitions. The Afirma GEC is a 
thyroid genomic test validated in a robust study design 
via two multicenter, prospective studies against blinded 
expert histopathology (34). This RNA expression ap-
proach reclassifies to benign about one-half of the his-
tologically benign patients with cytologically indetermi-
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nate nodules. This increases the diagnostic specificity of 
indeterminate cytology from 0% to 52%. Thus, about 
half of those with truly benign lesions can be removed 
from the surgical pool and conservatively followed as 
if they were cytologically benign. The remaining GEC 
“suspicious” patients are enriched for malignancy with 
a positive predictive value of about 40%. Given this in-
termediate ROM other factors are needed to decide if 
these patients should undergo a diagnostic hemithyroi-
dectomy or total thyroidectomy. The low frequency of 
BRAF, RET/PTC, PPARG mutations in AUS/FLUS 
and FN/SFN patients suggests that testing for these 
mutations/rearrangements to make this decision may 
be of low yield (37,38), although testing for RAS mu-
tations may be the most productive (34,38), especially 
if one found it acceptable to perform a total thyroidec-
tomy in the setting of a benign follicular adenoma with 
a RAS mutation (3,38). Analytic validity and clinical 
utility studies, as well as prospective multicenter clini-
cal validation of this gene mutation testing paradigm 
against blinded histopathology experts remain to be 
performed. 
Disclosure: RTK is a stockholder and employee of Veracyte, Inc. 
LSW has no conflict of interest. 
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